Butantan Institute director Dimas Covas at a news briefing in Sao Paulo, Brazil, on Thursday. The institute said it had requested emergency use approval for CoronaVac from the national health agency, Anvisa. Photo: AFP Butantan Institute director Dimas Covas at a news briefing in Sao Paulo, Brazil, on Thursday. The institute said it had requested emergency use approval for CoronaVac from the national health agency, Anvisa. Photo: AFP
Butantan Institute director Dimas Covas at a news briefing in Sao Paulo, Brazil, on Thursday. The institute said it had requested emergency use approval for CoronaVac from the national health agency, Anvisa. Photo: AFP

Coronavirus: a Sinovac Biotech vaccine is seen as 78 per cent effective in Brazil

  • Sao Paulo state government announcement paves the way for emergency use approvals and roll-out in array of countries and regions, including Hong Kong
  • It comes after interim data showed 79 per cent efficacy for another Chinese vaccine, developed by Sinopharm

Topic |   Coronavirus pandemic
Butantan Institute director Dimas Covas at a news briefing in Sao Paulo, Brazil, on Thursday. The institute said it had requested emergency use approval for CoronaVac from the national health agency, Anvisa. Photo: AFP Butantan Institute director Dimas Covas at a news briefing in Sao Paulo, Brazil, on Thursday. The institute said it had requested emergency use approval for CoronaVac from the national health agency, Anvisa. Photo: AFP
Butantan Institute director Dimas Covas at a news briefing in Sao Paulo, Brazil, on Thursday. The institute said it had requested emergency use approval for CoronaVac from the national health agency, Anvisa. Photo: AFP
READ FULL ARTICLE